BCMA-targeted LCAR-BCDR Cells · Relapsed/Refractory Multiple Myeloma
Reclassified as completed (was terminated)
Shanghai Changzheng HospitalPhase 1 NCT05376345 Registry history of NCT05376345 on ClinicalTrials.gov (opens the registry)
3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.
Reclassified as completed (was terminated)
Shanghai Changzheng HospitalPhase 1 NCT05376345 Registry history of NCT05376345 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 161 → 201 participants
Shanghai Changzheng HospitalNot applicable NCT07746635 Registry history of NCT07746635 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting
Shanghai Changzheng HospitalNot applicable NCT06196996 Registry history of NCT06196996 on ClinicalTrials.gov (opens the registry)
Changed
| Early Phase 1 | 15 | |
| Phase 1 | 1 | |
| Phase 1/2 | 2 | |
| Phase 2 | 10 | |
| Phase 2/3 | 2 | |
| Phase 4 | 3 |
Colorectal Cancer (8) · Diabetes (8) · Prostate Cancer (6) · Multiple Myeloma (3) · Leukemia (2) · Lupus (SLE) (2) · NASH / MASH (2) · Cholangiocarcinoma (1) · Chronic Kidney Disease (1) · Gastric Cancer (1)